Previous close | 2.0200 |
Open | 1.9800 |
Bid | 1.8000 x 2900 |
Ask | 2.1000 x 1100 |
Day's range | 1.9000 - 2.0300 |
52-week range | 1.7700 - 5.0400 |
Volume | |
Avg. volume | 143,547 |
Market cap | 110.691M |
Beta (5Y monthly) | 2.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.0400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.64 |
Cellectis, which gets a seat on Primera's board, will collaborate with Primera on the development of therapies for mitochondrial diseases, a group of genetic disorders. Under terms of the deal, if Primera chooses to exclusively license up to five co-developed therapies from Cellectis, it will be eligible to get up to $750 million in milestone payments.
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.